Via: GlobalNewswire
Rosemont, Ill., Dec. 27, 2021 (GLOBE NEWSWIRE) -- A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR) were higher than those for carotid endarterectomy (CEA), TCAR afforded greater quality-adjusted life years (QALY).
The study is published in the December 2021 issue of the Journal of Vascular Surgery.
Stroke is the fifth leading cause of mortality in the United States, accounting for one in every 19 deaths. Carotid artery disease causes up to 20% of strokes. Since its development in the 1950s, carotid endarterectomy has been the “gold standard” surgical therapy for the treatment of carotid disease. With the advent of endovascular technology in the 1990s, carotid angioplasty and stenting (CAS) emerged as an alternative mode of revascularization.
According to principal author Mahmoud Malas, MD, from the University of California, San Diego, “TCAR was developed to address the deficiencies associated with both CEA and TFCAS. Several studies have shown that TCAR has one-half the stroke rate of TFCAS. Further, it has similar stroke and death outcomes compared with CEA while reducing the incidence of cranial nerve injury and myocardial infarction.”
Read More: https://www.globenewswire.com/news-release/2021/12/27/2358053/0/en/Early-Evaluation-of-Transcarotid-Artery-Revascularization-TCAR-Versus-Carotid-Endarterectomy-CEA-Cost-Effectiveness.html
RSS Feed
